These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 16574282

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.
    Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi C, Omari S, Urassa A, Mshinda H, Jumanne A, Salim N, Shomari M, Aebi T, Schellenberg DM, Carter T, Villafana T, Demoitié MA, Dubois MC, Leach A, Lievens M, Vekemans J, Cohen J, Ballou WR, Tanner M.
    N Engl J Med; 2008 Dec 11; 359(24):2533-44. PubMed ID: 19064623
    [Abstract] [Full Text] [Related]

  • 26. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
    Sklar MJ, Maiolatesi S, Patterson N, Sedegah M, Limbach K, Teneza-Mora N, Chuang I, Hollis-Perry KM, Banania JG, Guzman I, Ganeshan H, Reyes S, Hollingdale MR, Wong M, Lindstrom A, Reyes A, Alcorta Y, Garver L, Bankard K, Belmonte A, Belmonte M, Huang J, Gowda K, Inoue S, Velasco R, Bergmann-Leitner E, Hutter J, Lee T, Adams N, Chaudhury S, Hunt D, Tamminga C, Berrie E, Bellamy D, Bittaye M, Ewer K, Diggs C, Soisson LA, Lawrie A, Hill A, Richie TL, Villasante E, Epstein JE, Duplessis CA.
    PLoS One; 2021 Dec 11; 16(9):e0256980. PubMed ID: 34495988
    [Abstract] [Full Text] [Related]

  • 27. Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein.
    Wang R, Epstein J, Charoenvit Y, Baraceros FM, Rahardjo N, Gay T, Banania JG, Chattopadhyay R, de la Vega P, Richie TL, Tornieporth N, Doolan DL, Kester KE, Heppner DG, Norman J, Carucci DJ, Cohen JD, Hoffman SL.
    J Immunol; 2004 May 01; 172(9):5561-9. PubMed ID: 15100299
    [Abstract] [Full Text] [Related]

  • 28. Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice.
    Shott JP, McGrath SM, Pau MG, Custers JH, Ophorst O, Demoitié MA, Dubois MC, Komisar J, Cobb M, Kester KE, Dubois P, Cohen J, Goudsmit J, Heppner DG, Stewart VA.
    Vaccine; 2008 Jun 02; 26(23):2818-23. PubMed ID: 18455276
    [Abstract] [Full Text] [Related]

  • 29. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.
    Prieur E, Gilbert SC, Schneider J, Moore AC, Sheu EG, Goonetilleke N, Robson KJ, Hill AV.
    Proc Natl Acad Sci U S A; 2004 Jan 06; 101(1):290-5. PubMed ID: 14694197
    [Abstract] [Full Text] [Related]

  • 30. Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid.
    Tartz S, Rüssmann H, Kamanova J, Sebo P, Sturm A, Heussler V, Fleischer B, Jacobs T.
    Vaccine; 2008 Nov 05; 26(47):5935-43. PubMed ID: 18804138
    [Abstract] [Full Text] [Related]

  • 31. Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya.
    Stoute JA, Heppner DG, Mason CJ, Siangla J, Opollo MO, Kester KE, Vigneron L, Voss G, Walter MJ, Tornieporth N, Cohen JD, Ballou WR.
    Am J Trop Med Hyg; 2006 Jul 05; 75(1):166-70. PubMed ID: 16837726
    [Abstract] [Full Text] [Related]

  • 32. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.
    Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, Krzych U, Delchambre M, Voss G, Dowler MG, Palensky J, Wittes J, Cohen J, Ballou WR, RTS,S Malaria Vaccine Evaluation Group.
    J Infect Dis; 2001 Feb 15; 183(4):640-7. PubMed ID: 11170991
    [Abstract] [Full Text] [Related]

  • 33. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen.
    Mettens P, Dubois PM, Demoitié MA, Bayat B, Donner MN, Bourguignon P, Stewart VA, Heppner DG, Garçon N, Cohen J.
    Vaccine; 2008 Feb 20; 26(8):1072-82. PubMed ID: 18258343
    [Abstract] [Full Text] [Related]

  • 34. Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies.
    Mehrizi AA, Zakeri S, Rafati S, Salmanian AH, Djadid ND.
    Parasite Immunol; 2011 Nov 20; 33(11):594-608. PubMed ID: 21883290
    [Abstract] [Full Text] [Related]

  • 35. Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines.
    Sedegah M, Rogers WO, Belmonte A, Belmonte M, Banania G, Patterson N, Ferrari M, Kaslow DC, Carucci DJ, Richie TL, Doolan DL.
    Vaccine; 2006 Mar 10; 24(11):1921-7. PubMed ID: 16298024
    [Abstract] [Full Text] [Related]

  • 36. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.
    Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, Patterson N, Guerrero M, Bennett JW, McGrath S, Ganeshan H, Belmonte M, Farooq F, Abot E, Banania JG, Huang J, Newcomer R, Rein L, Litilit D, Richie NO, Wood C, Murphy J, Sauerwein R, Hermsen CC, McCoy AJ, Kamau E, Cummings J, Komisar J, Sutamihardja A, Shi M, Epstein JE, Maiolatesi S, Tosh D, Limbach K, Angov E, Bergmann-Leitner E, Bruder JT, Doolan DL, King CR, Carucci D, Dutta S, Soisson L, Diggs C, Hollingdale MR, Ockenhouse CF, Richie TL.
    PLoS One; 2013 Mar 10; 8(2):e55571. PubMed ID: 23457473
    [Abstract] [Full Text] [Related]

  • 37. RTS,S/AS02A for malaria.
    Bojang KA.
    Expert Rev Vaccines; 2006 Oct 10; 5(5):611-5. PubMed ID: 17181435
    [Abstract] [Full Text] [Related]

  • 38. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.
    Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M, Cummings JF, Milman J, Tucker K, Soisson L, Stewart VA, Lyon JA, Angov E, Leach A, Cohen J, Kester KE, Ockenhouse CF, Holland CA, Diggs CL, Wittes J, Heppner DG, MSP-1 Malaria Vaccine Working Group.
    Vaccine; 2007 Jan 02; 25(1):176-84. PubMed ID: 16388879
    [Abstract] [Full Text] [Related]

  • 39. Live attenuated rubella vectors expressing Plasmodium falciparum circumsporozoite protein (Pf-CSP) provide a novel malaria vaccine platform in the rhesus macaque.
    Virnik K, Zhou W, Medvedev A, Walsh G, Perry-Anderson J, Majam V, Felber BK, Kumar S, Berkower I.
    Biochem Biophys Res Commun; 2021 Nov 05; 577():58-63. PubMed ID: 34507066
    [Abstract] [Full Text] [Related]

  • 40. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.
    Tamminga C, Sedegah M, Maiolatesi S, Fedders C, Reyes S, Reyes A, Vasquez C, Alcorta Y, Chuang I, Spring M, Kavanaugh M, Ganeshan H, Huang J, Belmonte M, Abot E, Belmonte A, Banania J, Farooq F, Murphy J, Komisar J, Richie NO, Bennett J, Limbach K, Patterson NB, Bruder JT, Shi M, Miller E, Dutta S, Diggs C, Soisson LA, Hollingdale MR, Epstein JE, Richie TL.
    Hum Vaccin Immunother; 2013 Oct 05; 9(10):2165-77. PubMed ID: 23899517
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.